{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:32:05Z","timestamp":1793377925002,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005895","name":"Fred Hutchinson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ymthe.2026.07.037","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:06:08Z","timestamp":1784304368000},"page":"5818-5830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Injectable bioinstructive microfoam for rapid bedside\/in vivo programming of CAR-T cells"],"prefix":"10.1016","volume":"34","author":[{"given":"Sirkka B.","family":"Stephan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoku","family":"West-Foyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Cavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inci Cevher","family":"Zeytin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Kiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras A.","family":"Heczey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-0100","authenticated-orcid":false,"given":"Matthias T.","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.07.037_bib1","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41591-024-03231-z","article-title":"CAR-T and cellular gene therapies are too expensive","volume":"30","author":"Dropulic","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.07.037_bib2","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","article-title":"Expanding access to CAR T cell therapies through local manufacturing","volume":"41","author":"Elsallab","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.07.037_bib3","first-page":"S253","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy","volume":"27","author":"Borgert","year":"2021","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ymthe.2026.07.037_bib4","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.07.037_bib5","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2026.07.037_bib6","first-page":"735.e1","article-title":"Health and Economic Impact of Vein-to-Vein Time in CAR T-Cell Therapy in the Second-Line Treatment of Relapsed\/Refractory Large B-Cell Lymphoma: A US Cost-Effectiveness Analysis","volume":"32","author":"Oluwole","year":"2025","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.ymthe.2026.07.037_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00086","article-title":"Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model","volume":"3","author":"Tully","year":"2019","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.ymthe.2026.07.037_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1206715","article-title":"\u201cWaitlist mortality\u201d is high for myeloma patients with limited access to BCMA therapy","volume":"13","author":"Ahmed","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.037_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41571-022-00628-y","article-title":"CAR T cells show promise in the frontline for high-risk LBCL","volume":"19","author":"Killock","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.07.037_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.07.037_bib11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41551-024-01219-1","article-title":"A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells","volume":"8","author":"Sin","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.07.037_bib12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jcyt.2023.07.012","article-title":"Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform","volume":"25","author":"Trainor","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.07.037_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-bioeng-070620-033348","article-title":"In Situ Programming of CAR T Cells","volume":"23","author":"Parayath","year":"2021","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.07.037_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.07.037_bib15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","article-title":"In vivo CAR T cells move into clinical trials","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.07.037_bib16","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.07.037_bib17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.07.037_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.07.037_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41587-025-02979-0","article-title":"The dawn of in vivo immune cell engineering in oncology","volume":"44","author":"Bot","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.07.037_bib20","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.ekir.2024.04.024","article-title":"Thrombotic Microangiopathy as an Emerging Complication of Viral Vector-Based Gene Therapy","volume":"9","author":"Schwotzer","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2026.07.037_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-0716-3786-9_23","article-title":"Evaluation of the Acute Anaphylactoid Reactogenicity of Nanoparticle-Containing Medicines and Vaccines Using the Porcine CARPA Model","volume":"2789","author":"Szebeni","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.07.037_bib22","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.07.037_bib23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.07.037_bib24","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41598-024-52685-1","article-title":"A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient","volume":"14","author":"Schober","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.07.037_bib25","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1016\/j.ymthe.2023.08.003","article-title":"CD90-targeted lentiviral vectors for HSC gene therapy","volume":"31","author":"Berckmueller","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.07.037_bib26","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1038\/s41467-024-48753-9","article-title":"Liquid foam improves potency and safety of gene therapy vectors","volume":"15","author":"Fitzgerald","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.07.037_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41434-026-00592-7","article-title":"Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma","volume":"33","author":"Stephan","year":"2026","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.07.037_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.07.037_bib29","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.07.037_bib30","article-title":"Context-specific synthetic T cell promoters from assembled transcriptional elements","author":"Appelbaum","year":"2023","journal-title":"Res. Sq"},{"key":"10.1016\/j.ymthe.2026.07.037_bib31","series-title":"Synthetic promoters enhance gene therapy precision","author":"Roberts","year":"2025"},{"key":"10.1016\/j.ymthe.2026.07.037_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14020369","article-title":"Challenges and Opportunities in Lentivirus Viral Vector Manufacturing for In Vivo Applications","volume":"14","author":"Barbieri","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2026.07.037_bib33","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.07.037_bib34","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.07.037_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2025-269","article-title":"Safety and efficacy of AZD0120, a BCMA\/CD19 dual-targeting CAR T-cell therapy, in relapsed\/refractory multiple myeloma: Preliminary results from the DURGA-1 Phase 1b\/2 study","volume":"146","author":"Richard","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.07.037_bib36","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.07.037_bib37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2024-206596","article-title":"Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma","volume":"144","author":"Deng","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.07.037_bib38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2025-670","article-title":"Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results","volume":"146","author":"Westin","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.07.037_bib39","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","article-title":"Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells","volume":"40","author":"Agarwalla","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.07.037_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2024.04.040","article-title":"Biomaterial-based scaffolds for direct in situ programming of tumor-infiltrating T lymphocytes","volume":"370","author":"Inamdar","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.07.037_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.07.037_bib42","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/nm1676","article-title":"T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626006052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626006052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:36:53Z","timestamp":1793374613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626006052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1525001626006052"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.07.037","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Injectable bioinstructive microfoam for rapid bedside\/in vivo programming of CAR-T cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}